G. Anker

发表

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

T. Aas, P. Lønning, A. Nysted, 2011, PloS one.

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

Steinar Lundgren, Stian Knappskog, Lars Fredrik Engebretsen, 2008, PloS one.

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Jürgen Geisler, Per Eystein Lønning, T. Aas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer

A. Nobel, D. Botstein, C. Fan, 2006, Molecular Cancer Therapeutics.

Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.

P. Lønning, G. Anker, P. Ueland, 1999, Clinical chemistry.

cancer clinical treatment response in locally advanced breast Gene expression profiles do not consistently predict the

A. Nobel, D. Botstein, C. Fan, 2011 .

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

J. Bergh, P. Malmström, H. Holte, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

P. Lønning, A. Howell, G. Anker, 2001, Breast Cancer Research and Treatment.

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer

G. Anker, P. Ueland, E. Lien, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

J. Bergh, P. Malmström, B. Erikstein, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring of disseminated tumor cells in bone marrow in high‐risk breast cancer patients treated with high‐dose chemotherapy

J. Bergh, J. Nesland, S. Lundgren, 2006, International journal of cancer.

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.

P. Lønning, J. Geisler, G. Anker, 1996, European journal of cancer.

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women.

P. Lønning, G. Anker, J. Holly, 1998, Maturitas.

Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen

P. Lønning, G. Anker, P. Ueland, 2006, International journal of cancer.

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

O. Mariani, J. Bonneterre, L. Dirix, 2000, European journal of cancer.

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

P. Lønning, J. Geisler, G. Anker, 2001, British Journal of Cancer.

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

P. Lønning, G. Anker, P. Ueland, 1990, Cancer research.

Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine.

P. Lønning, G. Anker, P. Ueland, 1997, Biochemical Society Transactions.

Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients

P. Lønning, M. Dowsett, J. Geisler, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

P. Lønning, M. Dowsett, J. Geisler, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.

P. Lønning, G. Anker, A. Aakvaag, 1998, Scandinavian journal of clinical and laboratory investigation.

Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

T. Aas, S. Geisler, H. Johnsen, 2003 .

CHEK 2 Mutations Affecting Kinase Activity Together With Mutations in TP 53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

P. Lønning, S. Lundgren, S. Knappskog, 2009 .

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

P. Lønning, J. Nesland, S. Lundgren, 2012, Breast Cancer Research.

Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients

P. Lønning, G. Anker, M. Tally, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

P. Lønning, M. Dowsett, J. Geisler, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postrnenopausal breast cancer patients (MBC) failing tamoxifen (TAM)

O. Mariani, J. Bonneterre, L. Dirix, 1998 .

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

P. Lønning, S. Lundgren, S. Knappskog, 2012, Breast Cancer Research.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

J. Bergh, P. Malmström, H. Holte, 2000, The Lancet.

Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer.

Ludvig Paul Muren, L. Muren, G. Anker, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review

E. Fors, S. Lundgren, L. Oldervoll, 2010, Psycho-oncology.

Relations between sex hormones, sex hormone binding globulin, insulin‐like growth factor‐I and insulin‐like growth factor binding protein‐I in post‐menopausal breast cancer patients

P. Lønning, H. Adlercreutz, G. Anker, 1995, Clinical endocrinology.

[Recommendations on contents of medical reports in rectal carcinoma: I: Surgical report and pathology findings. Orientating aids in interdisciplinary management].

G. Anker, K. Jauch, J. Engel, 1998, Zentralblatt fur Chirurgie.

The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer

P. Lønning, A. Børresen-Dale, I. Gram, 2006, Clinical Cancer Research.

The Novel p 21 Polymorphism p 21 G 251 A Is Associated with LocallyAdvanced Breast Cancer

I. Gram, S. Lundgren, S. Knappskog, 2006 .

Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen.

P. Lønning, G. Anker, P. Ueland, 1999, Cancer letters.

Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review

E. Fors, S. Lundgren, L. Oldervoll, 2010, Psycho-oncology.

Rehabilitation of Breast Cancer Patients

E. Fors, G. Anker, I. Thune, 2009 .